Roche

News

Roche culls myostatin candidate from obesity pipeline

Roche has abandoned the development of one of its obesity candidates, emugrobart, and returned rights to originator Chugai Pharma.

News

Roche, Viking, and Syntis showcase obesity drug candidates

A flurry of clinical readouts for new weight-loss therapies has seen Roche, Viking, and Syntis all showing off new drug candidates.

News

Roche's IgAN hopeful sefaxersen passes phase 3 test

Roche has staked a claim to the increasingly crowded IgA nephropathy (IgAN) category with phase 3 data for Ionis-partnered sefaxersen.

News

WCLC: Lung cancer news from BioNTech, Akeso, and Roche

As the World Conference on Lung Cancer (WCLC) draws to a close, here are some late-breaking clinical trial data that made waves at the congress.

News

Reviews underway of first drug for rare disease MOGAD

Patients with rare autoimmune disease MOGAD could be months away from having a first approved therapy, as the FDA starts a review of Roche's Enspryng.

News

Person holds hand of elderly lady; grey colour scheme

Major trial of Roche Alzheimer's drug kicks off in Europe

The PrevenTRON trial of Roche's Brainshuttle drug trontinemab in preclinical Alzheimer's disease has gotten underway in the UK.

Roche culls myostatin candidate from obesity pipeline

Roche, Viking, and Syntis showcase obesity drug candidates

Roche's IgAN hopeful sefaxersen passes phase 3 test

WCLC: Lung cancer news from BioNTech, Akeso, and Roche

Reviews underway of first drug for rare disease MOGAD

Major trial of Roche Alzheimer's drug kicks off in Europe

Iambic prices its IPO, seeking to raise up to $160m

Discover a new era of healthcare panel engagement: Grounded ...

Roche

Editor's Picks